Table 1.
EBV-associated cancer cell lines used in the study
| Cancer cell lines (origin) | HLA typing* | HLA-matched allogeneic EBV-specific T-cell products |
| SNU719 (GC) | A*24:02, 24:02; B*07:02, 52:01; C*07:02,12:02 | TIG-001 and TIG-004 |
| C17 (NPC) | A*02:01, 26:01; B*44:02,51:01; C*05:01,14:02 | TIG-002 |
| C666.1 (NPC) | B*58:02; C*03:04 | TIG-003 |
| SNT16 (NK/T) | A*02:01, 24:02; B*48:01, 52:01; C*08:03, 12:02 | TIG-001 and TIG-002 |
| YCLLE1 (GC) | A*24:02, 24:02; B*15:07, 40:01; C*03:03, 08:22 | TIG-001 and TIG-002 |
| GP202 (GC) | A*01:01, 24:02; B*08:01, 18:01; C*07:01, 07:01 | TIG-001 |
| NPC43 (NPC) | A*11:01, 11:01; B*50:01, 50:01; C*06:02, 06:02 | TIG-006 |
| L591 (HL) | A*01:01, 33:01; B*08:01, 35:03; C*03:04, 07:01 | TIG-002 |
| LCL-01 (B cells) | A*24:02, 24:02;B*08:02,50:01; C*05:02,07:02 | TIG-001 |
| LCL-02 (B cells) HEK293T |
A*02:01,33:01; B*58:02,08:02; C*04:01,14:02 A*02:01,03:01; B07:02,35:01; C*07:02,07:02 |
TIG-002 and TIG-003 TIG-002 |
*HLA alleles matched between the cancer cell lines and allogeneic T-cell products are underlined.
EBV, Epstein-Barr virus; HLA, human leukocyte antigen; LCL, lymphoblastoid cell line.